Hormonal Manipulation of Benign Prostatic Hyperplasia

The document reviewed hormonal treatments for benign prostatic hyperplasia (BPH), focusing on 5α-reductase inhibitors (5-ARIs) like finasteride and dutasteride, which were effective in reducing prostate size and symptoms. Combination therapies, particularly dutasteride with tamsulosin, showed superior results, especially for larger prostates. LHRH antagonist cetrorelix also demonstrated significant improvements. The potential oncological risks of 5-ARIs, including high-grade prostate cancers and impacts on fertility, were discussed. Novel treatments involving GHRH and LHRH antagonists showed promise in reducing prostate size and improving symptoms, suggesting new avenues for BPH treatment.